KEYNOTE-024 update: pembrolizumab vs platinum-based chemotherapy in NSCLC

Martin Reck, MD, PhD, German Center of Lung Research, Grosshansdorf, Germany, discusses the KEYNOTE-024 trial, involving pembrolizumab compared to platinum-based chemotherapies in participants with metastatic non-small cell lung cancer (NSCLC). The study saw substantial improvement of overall survival (OS) favoring pembrolizumab, with the 5-year survival rate doubling and a 5-year OS rate of 31.9%. Professor Reck explains that there was an opportunity for patients who experienced disease progression after benefitting from pembrolizumab to receive a second course of treatment, with an overall response rate of 33% and stabilization of 50%. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).